D-W Wu

DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer

D-W Wu, M-C Lee, Jiaan‐Der Wang et al. · Oncogene · 2013 · 94 citations · Full text

Tumor Biology, Medicine, Pathology +11

c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT

D-W Wu, N-Y Hsu, Y-C Wang et al. · Oncogene · 2014 · 81 citations

Poor Outcomes, Medicine, Immunology +9

Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression

D-W Wu, T-C Wu, J-Y Wu et al. · Oncogene · 2013 · 78 citations · Full text

Paxillin Confers, Oncology, Erk-mediated Bcl-2 Expression +8

TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells

D-W Wu, Tsung‐Chih Chen, Hsu‐Shan Huang et al. · Cell Death and Disease · 2016 · 42 citations · Full text

Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability

D-W Wu, Ching‐Yu Chen, C-L Chu et al. · Oncogene · 2015 · 39 citations · Full text

Mcl-1 Protein Stability, Receptor Tyrosine Kinase, Kinase Inhibitors +8